Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →
logo
Get CLEATUS

NIH Research Evaluation and Commercialization Hubs (REACH)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institutes of Health is preparing to launch the Research Evaluation and Commercialization Hubs (REACH) program to accelerate the translation of academic biomedical research into market-ready products that enhance patient care and public health. Five new academic entrepreneurship hubs will be funded to provide early-stage financial support, technical guidance, and mentorship in product development and commercialization, with a focus on high-priority technologies aligned with NIH’s mission. These hubs will collectively form a consortium designed to identify promising innovations, fund feasibility and proof-of-concept studies, and connect researchers with expertise across science, regulation, reimbursement, business, law, and project management while offering hands-on entrepreneurship training. Public-private partnerships and non-federal matching funds are essential components of the program, which builds on prior REACH initiatives and aligns with the Phase 0 Proof of Concept Partnership pilot authorized under federal legislation extended through 2031. The program also supports broader national priorities such as workforce development, strengthening government-industry-academia collaboration, and addressing health disparities in underserved and rural communities. Applications are not yet open, but the announcement allows potential applicants time to establish collaborations and refine project proposals ahead of the formal solicitation.

General Info

NIH to fund five hubs accelerating biomedical research commercialization with public-private partnerships and workforce development.

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
View Agency Profile
Office AddressUS
Contacts
NIH SEED (Small business Education and Entrepreneurial Development) Office
contact@example.gov
+1 (555) 000-0000

Full Description

Show more

The National Institutes of Health (NIH), including all of its Institutes and Centers, plans to publish a Notice of Funding Opportunity inviting eligible colleges, universities, and nonprofit organizations to apply for the NIH Research Evaluation and Commercialization Hub (REACH) program. The REACH program helps move promising biomedical discoveries from academic research into real-world products that can improve patient care and public health. Through this opportunity, NIH plans to fund five new academic entrepreneurship hubs. These hubs will support researchers by providing early-stage funding, technical and business resources, and mentorship in product development and commercialization. The hubs will focus on high-priority technologies that align with NIH's mission. Together, the funded hubs will form a technology development consortium that will help: 

  • Identify the most promising academic biomedical technologies; 
  • Fund early product-development work, such as feasibility studies, prototypes, and proof-of-concept studies; 
  • Provide access to expertise in science, regulation, reimbursement, business, law, and project management; and 
  • Offer entrepreneurship training and hands-on commercialization experience. 

Public-private partnerships and non-federal matching funding will be important to the program's success. The five awardees will build on lessons learned from previous REACH hubs and support the goals of the Phase 0 Proof of Concept Partnership pilot program, as authorized by the 2011 SBIR/STTR Reauthorization Act (P.L. 112-81 Section 5127) and extended through fiscal year 2031 under the Small Business Innovation and Economic Security Act (P.L. 119-83). The REACH program also supports federal research and development priorities, including preparing the 21st-century workforce, moving technologies from the lab to the marketplace, strengthening partnerships among government, industry, and academia, and addressing local health needs, particularly in medically underserved and/or rural areas.

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. 

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Protein ENGineering (PENG)
Solicitation # DARPA-PS-26-129
The Defense Advanced Research Projects Agency (DARPA) is seeking innovative proposals under the Protein ENGineering (PENG) program, solicited through DARPA-PS-26-129, to develop a universal, software-defined platform for precise, programmable editing of endogenous proteins. The goal is to transform proteome engineering from fragmented, target-specific tools into an integrated system capable of directly recognizing, modifying, and rewriting proteins within complex biological environments using modular targeting, generalizable effector chemistries, and multiplexed control systems. Performers are expected to leverage novel splicing, ligation, and co-translational techniques to achieve these modifications in high-fidelity cellular models such as organoids, with progression from foundational validation to robust tissue-level demonstrations. The program is structured over a 42-month total period of performance, divided into an 18-month Base Phase 1, a 6-month Option Phase 1 for capability demonstration, and an 18-month Option Phase 2, spanning fiscal years 2027 through 2030. Performance will occur primarily at the contractor’s facility, with critical milestones requiring on-site demonstrations and DARPA team visits in Arlington, Virginia, where final evaluation and acceptance will take place. Proposals must adhere to strict formatting and documentation standards, including structured cost submissions using designated worksheets with sequentially numbered Reference Document IDs (e.g., EQ001, MAT010) for all equipment and materials over $5,000, supported by vendor quotes and detailed justifications. All cost estimates must comply with Federal Acquisition Regulation cost principles, and no deletion of template columns or cells is permitted. Key personnel—regardless of salary support—must be explicitly listed, and option periods must maintain continuity in document numbering with the base phase. While no explicit contract clauses, evaluation factors, or award methodology are provided, the solicitation emphasizes transparency, traceability, and compliance with Controlled Unclassified Information handling standards. Contractors must be prepared to submit proposals electronically by the October 19, 2026 deadline, with funding ceilings of up to $225,000 for Phase 1, $225,000 for Phase 2, and $160,000 for potential institutional innovation program participation, resulting in a maximum potential contract value of $610,000. No small business set-asides, socioeconomic certifications, or specific invoicing or payment office details are specified,
Defense Advanced Research Projects Agcy

POSTED

2 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

4 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
SBIR / STTR
Universal Cell Culture Platform for Rapid Establishment of Species-Agnostic Cell Lines and Autonomous Culture Operations
Solicitation # DPA26BZ05-DV020
Establishing cell culture systems for non-model vertebrate and invertebrate species remains a major bottleneck in biotechnology, severely limiting progress in gene-drive research, biocontrol development, and species-specific biomanufacturing. Current methods require years of labor-intensive, operator-dependent optimization tailored to each species, with protocols that rarely transfer between labs and lack reproducibility. This contract seeks an integrated platform that eliminates these inefficiencies by enabling rapid, universal derivation of stable cell lines from any species—regardless of taxonomic distance from established models—through species-agnostic biological techniques. These methods must support primary cell isolation, induced pluripotent stem cell reprogramming, and long-term maintenance using broadly applicable media, substrates, and reprogramming strategies that do not rely on species-specific reagents or markers, while also enabling validation of pluripotency, genomic stability, and differentiation potential in the absence of conventional reference tools. To accelerate this process, the platform must pair these biological innovations with fully autonomous, closed-loop automation capable of conducting high-throughput, parallelized experiments with minimal human intervention. The system must independently control environmental parameters at the vessel or well level, perform routine and complex cell culture operations—including feeding, passaging, imaging, and sampling—and use integrated machine-learning-driven analysis to interpret cellular health and morphology, then iteratively propose and execute new experimental conditions. This automation must generate fully digitized, transferable protocols that are reproducible across instruments and locations, compressing years of development into weeks or months. Where applicable, the platform must further support gene-drive and genetic-biocontrol research by providing validated cellular testbeds—including germline or developmentally relevant cell types—that enable in vitro measurement of homing efficiency, off-target activity, stability, and fitness costs, along with molecular containment and safety evaluation strategies. All work under the gene-drive component must remain strictly in vitro, with no environmental release or creation of gene-drive-competent organisms permitted, and must incorporate responsible research practices, biosafety protocols, and institutional oversight. The ultimate goal is a unified system that seamlessly links universal cell culture methods with automated optimization and targeted genetic validation to rapidly enable biological capabilities across the full spectrum of understudied species.
Defense Advanced Research Projects Agency

POSTED

5 days ago

DEADLINE

in 16 days
View Details
NAICS: 541714
New
Federal
Evaluation of a Lead NNMT Inhibitor in Humanized M
Solicitation # 75N98026Q00941
The National Institutes of Health, Office of the Director, intends to award a non-competitive, firm-fixed price contract to GemPharmatech LLC for the evaluation of a lead NNMT inhibitor using a humanized nicotinamide N-methyltransferase mouse model, a model uniquely developed and maintained by GemPharmatech under prior NIH funding. This acquisition is conducted under streamlined commercial item procedures and is not expected to exceed the simplified acquisition threshold, with authority derived from FAR 12.603 and 41 U.S.C. 1901, and justified under the sole source exception for unique capabilities, as GemPharmatech is the only entity with the cryopreserved sperm and breeding resources necessary to regenerate the required mouse colony essential for generating scientifically relevant efficacy data due to the inhibitor's species-specific activity. The solicitation number is 75N98026Q00941, issued as a combined synopsis and solicitation without competitive procedures, and responses are due by August 19, 2026. The work falls under NAICS code 541714 for Research and Development in Biotechnology with a small business size standard of 1,000 employees, and this requirement is not set aside for small business. The contract will be managed by the NIH Office of Acquisitions based in Bethesda, Maryland, with the primary point of contact being Johnstona C. Johnston, reachable via email. All provisions and clauses follow those in effect through the Federal Acquisition Circular dated August 4, 2026, and the notice serves as the complete and only solicitation document; no additional written solicitation will be issued. The performance location is not specified beyond the federal agency's administrative details.
National Institutes Of Health Olao

POSTED

5 days ago

DEADLINE

in 10 days
View Details
NAICS: 541714
New
Federal
Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak
Solicitation # 75F40126Q00327
The contract seeks sequencing services for the Bundibugyo virus disease (BDBV) during the 2026 outbreak, with solicitation number 75F40126Q00327 issued by the FDA Office of Acquisition and Grant Services under the U.S. Department of Health and Human Services. The opportunity was posted on August 4, 2026, with responses due by August 10, 2026, at 4:00 PM Eastern Time, and no set-aside is applicable, meaning it is open to all eligible vendors. The North American Industry Classification System code is 541714, indicating it falls under research and development in the biological sciences. Performance location details are not specified, but the contracting office is based in Rockville, Maryland, 20852, and the primary point of contact is Ryan Alexander, reachable via email at ryan.alexander@fda.hhs.gov. The solicitation is accessible through the SAM.gov platform for further details and submission.
FDA Office Of Acq Grant Svcs

POSTED

5 days ago

DEADLINE

in 1 day
View Details
NAICS: 541714
New
Federal
Yeast Two-Hybrid (Y2H) Screening Service
Solicitation # 1232SA26Q1181
The U.S. Department of Agriculture’s Agricultural Research Service is soliciting quotations for Yeast Two-Hybrid (Y2H) Screening Services under solicitation number 1232SA26Q1181, issued as a combined synopsis and solicitation in accordance with FAR Part 12 for commercial items. This acquisition is exclusively reserved for small business concerns, with the North American Industry Classification System code 541714 for Research and Development in Biotechnology and a size standard of 1,000 employees, making it a total small business set-aside. Only responsible small business sources may submit quotations, which will be evaluated without the issuance of a separate written solicitation. The quote submission deadline is August 28, 2026, at 22:00 Eastern Time, with the solicitation publicly posted on August 4, 2026, and responses due to the USDA ARS office located in Beltsville, Maryland. The performance of the Y2H screening services is required to take place in Ithaca, New York, 14853. The primary point of contact for inquiries is Kerrie Hodges, reachable via email at kerrie.hodges@usda.gov. The contract is being procured by the USDA ARS Affiliated Programs and Development office and is intended to support research activities for the Robert W. Holley Center for Agriculture and Health. Interested parties must submit their quotations through the SAM.gov platform using the provided UI link, and all responses must comply with the commercial item procurement procedures outlined in FAR Part 12. No further documentation or separate solicitation documents will be issued.
USDA Ars Afm Apd

POSTED

5 days ago

DEADLINE

in 19 days
View Details
NAICS: 541714
New
Federal
Genotyping
Solicitation # 1232SA26Q0963
This solicitation, numbered 1232SA26Q0963, is a combined synopsis and request for quotation for genotyping services under FAR Part 12, with no separate written solicitation to follow. It is a total small business set-aside, restricted exclusively to small businesses as defined by the NAICS code 541714 and the 1,000-employee size standard. All responsible small business sources are encouraged to submit quotations, which will be evaluated based on criteria outlined in Attachment 1, which includes the full terms, conditions, and evaluation parameters. The solicitation incorporates provisions and clauses by reference, accessible electronically at www.acquisition.gov. The contract is issued by the USDA ARS AFM APD, with the office located in Beltsville, Maryland, and performance required in Maricopa, Arizona, ZIP 85138. Responses are due by August 12, 2026, at 7:00 p.m. Eastern Time, and the opportunity was posted on August 4, 2026. The primary point of contact for inquiries is Frank Palmer, reachable via email at frank.palmer@usda.gov, and additional details can be viewed on the SAM.gov website at the provided UI link.
USDA Ars Afm Apd

POSTED

5 days ago

DEADLINE

in 3 days
View Details
NAICS: 541714
New
Federal
AN11--36C25226R0084 - TBI research with Arraystar Inc FY2026
Solicitation # 36C25226R0084
The Department of Veterans Affairs is seeking information from potential vendors to support a sole source procurement for Methylated and hydroxymethylated DNA immunoprecipitation sequencing (MeDIP-seq and hMeDIP-seq) services under solicitation number 36C25226R0084. This effort is part of a TBI research project at the William S Middleton VA Medical Center in Madison, Wisconsin, aimed at understanding epigenetic changes—specifically the roles of 5-methylcytosine and 5-hydroxymethylcytosine—in secondary brain damage following trauma. The contract requires comprehensive sequencing and data analysis of mouse brain tissue samples from adult and aged males and females to identify sex- and age-specific patterns. The work must be performed using the same tissue samples for both MeDIP and hMeDIP to minimize variability and ensure reliable comparative results. The vendor will deliver raw sequencing data in Fastq format, quality control reports, analytical summaries, and final project reports in Excel, PDF, and PNG formats within 56 to 70 days of contract start. Submission of capability statements is required by August 10, 2026, via email only, with no phone inquiries accepted, and must include customer references and technical proof of capability. This is not a solicitation or request for proposals but a sources sought notice to justify a sole source award under 41 U.S.C. 1901, as the VA believes only one vendor can meet the highly specialized scientific requirements. The principal investigator will evaluate all submissions due to the technical nature of the research and will determine vendor suitability. The contract, if awarded, will be a firm fixed price agreement for one year, with no option periods, running from August 10, 2026, to August 9, 2027. All deliverables must be transmitted via USB drive, as the research laboratory operates in an affiliate space disconnected from the VA network. Responses must be emailed to Tiarrah Turner at the VA Great Lakes Acquisition Center in Milwaukee, Wisconsin, with attachments not exceeding 8 MB each. The government retains full discretion to proceed with sole source negotiation regardless of responses received. No federal funds are allocated under the Recovery Act for this procurement.
252-NETWORK Contract Office 12 (36C252)

POSTED

6 days ago

DEADLINE

in about 17 hours
View Details
NAICS: 541714
New
Grant
Emerging Infections Network - Research for Preventing, Detecting, and Managing Travel-associated Infectious Diseases
Solicitation # RFA-CK-26-035
The Centers for Disease Control and Prevention, under the Department of Health and Human Services, is soliciting applications through RFA-CK-26-035 to establish a dual-component surveillance network aimed at detecting, preventing, and managing infectious diseases among international travelers. The initiative targets two key environments: clinic-based sentinel sites serving travelers and wastewater-based monitoring at major international transportation hubs, including airports in Addis Ababa, Nairobi, Istanbul, Bangkok, Seoul, and São Paulo. The goal is to enhance early outbreak detection, refine diagnostic and treatment strategies, improve genomic surveillance, and strengthen global health security by generating timely, actionable public health data. Applications may be submitted for Component A, Component B, or both, with the understanding that if a proposal for both components is top-ranked, only Component B will be funded. The program is structured as a cooperative agreement with a five-year performance period beginning September 1, 2027, and an estimated total funding range of $8.75 million to $30 million across both components, with annual funding tiers specified per component. Applicants must adhere to strict submission protocols using the NIH SF-424 (R&R) application package, including a 12-page research strategy per component and a 1-page specific aims section, with no more than 10 PDF attachments allowed in the appendix. Critical requirements include registration in SAM.gov for a Unique Entity ID, eRA Commons registration for all key personnel, IRB approval for human subjects research, OMB-PRA clearance for data collection, and submission of a Bona Fide Agent document, an indirect cost agreement, and a report on proposal overlap if applicable. The CDC will maintain substantial programmatic involvement, requiring prior approval for publications and active collaboration in project execution. Evaluation is based on five scientific merit criteria—Significance, Investigators, Innovation, Approach, and Environment—scored on a 1-to-9 scale, with the final award decision guided by scientific merit, program relevance, portfolio balance, and geographic distribution, not cost. Payment is administered under federal grant rules, with indirect costs capped at 15% using the de minimis rate unless an approved rate is provided. Final reports are due 120 days after project completion, and all data must be shared via the global GLOWACON platform under standardized protocols for wastewater sampling, metagenomic sequencing, and bioinformatics analysis.
Centers For Disease Control And Prevention

POSTED

7 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Federal
Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Solicitation # 75A50126R00001_RFP_PreSolNotice_NPIVS-2027
The U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is seeking qualified contractors to support the ongoing Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. Contractors must be capable of furnishing all necessary services, personnel, equipment, materials, and U.S.-based facilities to produce vaccines, antigens, and adjuvants for pandemic influenza and other viruses with pandemic potential. To be eligible, offerors must either hold an active U.S. influenza vaccine license from the FDA or have submitted a Biologics License Application for a seasonal or pandemic influenza vaccine. The program demands the generation and submission of comprehensive regulatory data—including analytical, nonclinical, clinical, and chemistry, manufacturing, and controls (CMC) information—to the FDA to enable rapid decision-making and maintain manufacturing readiness during interpandemic periods. The anticipated contract is an indefinite delivery, indefinite quantity (IDIQ) vehicle with a base performance period of 60 months and the potential to extend up to 120 months if all option periods are exercised, combining both cost-reimbursement and firm-fixed-price task orders. Performance is expected to occur primarily within the United States, with the place of performance designated as Washington, D.C., and the contracting office located at 400 7th Street SW. Proposals must be submitted electronically via SAM.gov by the deadline of August 15, 2026, and are subject to evaluation based on mandatory qualification requirements, with full evaluation factors and source selection criteria expected to be detailed in the forthcoming Request for Proposals. The solicitation number is 75A50126R00001, and the NAICS code is 541714 for research and development in biotechnology. The primary point of contact for inquiries is Laura Saddison, BARDA Contracting Officer, reachable at Laura.Saddison@hhs.gov. No set-aside is planned, and full and open competition is anticipated. While packaging, marking, inspection procedures, and specific invoicing methods are not defined in this presolicitation, contractors should prepare to comply with FDA regulatory standards and anticipate the use of federal systems such as WAWF for payment processing. No contracting officer’s representative or technical representative has been designated yet, and all certifications and representations will be required upon formal proposal submission.
Barda - Aspr / Daappo / Barda Dcma

POSTED

9 days ago

DEADLINE

in 6 days
View Details
NAICS: 541714
Federal
Convergence Special Notice
Solicitation # DARPA-SN-26-108
The Convergence program seeks to revolutionize environmental monitoring for defense operations by integrating synthetic biology and engineering to create advanced microbial biosensors capable of detecting chemical and pharmaceutical hazards in austere environments. Leveraging non-pathogenic microbial consortia built on well-characterized, safe host organisms like E. coli, the initiative focuses on developing modular biological systems that translate environmental inputs into standardized, detectable outputs. The program’s development follows a structured four-tiered approach, progressing from component-level design and integrated payload engineering to full system integration within a microbial chassis, ultimately aiming for a deployable platform ready for U.S. and international regulatory certification. This systematic progression ensures that each layer of functionality is rigorously validated before scaling to operational readiness. To enable safe, responsible, and globally viable deployment, the program includes a dedicated ecosystem of testing and collaboration. Performance and safety validation will first occur within the United States before exploring international adoption, with two specialized working groups guiding the process: one focused on navigating socio-political landscapes and local environmental regulations, and another managing cooperative use cases and deployment protocols with global allies. Administered by DARPA, the solicitation under number DARPA-SN-26-108 invites multidisciplinary teams in synthetic biology, environmental science, and engineering to contribute to this initiative, with responses due by August 6, 2026. The program is headquartered in Arlington, Virginia, and is led by Mark Salvador, with the goal of delivering a scalable, secure, and globally interoperable biosensor platform for the protection of military personnel.
Defense Advanced Research Projects Agcy

POSTED

10 days ago

DEADLINE

in 3 days
View Details
NAICS: 541714
Federal
Multiscale Reasoning For Human Physiology RFI
Solicitation # DARPA-SN-26-100
The Defense Advanced Research Projects Agency’s Biological Technologies Office is seeking input on cutting-edge technologies that enable multiscale reasoning across human physiology through this Request for Information, identified as DARPA-SN-26-100. The focus is on emerging tools including artificial intelligence systems, foundation models, computational frameworks, and datasets capable of integrating biological, physiological, and clinical data across multiple scales—from molecular and cellular levels to organ systems and whole-body responses. The goal is to advance the ability to model, predict, and interpret complex human physiological behavior using AI and data-driven approaches, with interest in non-traditional performers and innovative solutions from industry, academia, government labs, and healthcare organizations. Responses are due by August 10, 2026, and the solicitation falls under NAICS code 541714 for research and development in the physical, engineering, and life sciences. All submissions should be directed to Dr. Roozbeh Jafari, Program Manager at DARPA/BTO, via bioreasoning@darpa.mil. The office is located in Arlington, Virginia, and while no specific place of performance is defined, selected technologies may be developed and evaluated through future DARPA programs. This RFI does not constitute a solicitation for proposals or obligations but aims to inform upcoming funding opportunities in the field of physiological modeling and AI-driven biological insight.
Defense Advanced Research Projects Agcy

POSTED

10 days ago

DEADLINE

in 11 days
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NAICS: 518210
New
Grant
Partnership with Common Fund Data Ecosystem ResourcesThe National Institutes of Health, through the Office of Strategic Coordination and the Common Fund, is seeking partnerships between Common Fund data programs and non-CF biomedical data resources to improve the reusability and integration of Common Fund datasets within broader biomedical data ecosystems. The initiative aims to advance the FAIR principles—Findable, Accessible, Interoperable, and Reusable—by fostering collaborations that connect Common Fund data with established NIH resources such as the HEAL Data Ecosystem, BRAIN Initiative, Cancer Research Data Commons, ImmPort, TOPMed, the National Library of Medicine, and the Medical Imaging and Data Resource Center. These partnerships are intended to develop tools, infrastructure, or workflows that enhance data linkage, interoperability, and community access, thereby maximizing the scientific impact of Common Fund investments. This funding opportunity does not support clinical trials and is focused exclusively on non-research infrastructure activities that strengthen data ecosystem integration. The solicitation is a forecast posting with no formal application window yet open, but interested entities should prepare proposals that demonstrate clear collaboration plans with at least one eligible non-CF NIH data resource. Inquiries and correspondence should be directed to the Common Fund Data Ecosystem Program via the provided email address. The effort is part of a broader strategy to unify fragmented biomedical data assets and create a more cohesive, user-friendly landscape for data discovery and reuse across the research community.
Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services

POSTED

4 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
Transformative Technologies for Experimental and Computational RNome Characterization and Functional AnalysisThe NIH Common Fund, in collaboration with multiple NIH Institutes and Centers, is preparing to issue a funding opportunity for the Transformative Technologies initiative under the RNomics program, aimed at developing groundbreaking experimental and computational tools to characterize the full spectrum of RNA molecules in biological systems. This initiative targets high-risk, early-stage innovations that overcome significant limitations in current RNA analysis methods, with a focus on technologies for sequencing RNA, detecting chemical modifications, studying RNA functionality, and analyzing RNA across individual molecules, cells, and tissues. Projects will be structured in two phases, with Phase 1 supporting initial development and proof-of-concept work, and successful proposals eligible for transition to Phase 2, where validated, scalable tools will be delivered for broad community use. The program emphasizes the creation of resources that enable integrated analysis of RNA sequences, structures, modifications, locations, interactions, and functions to deepen understanding of health and disease mechanisms. While applications are not yet being accepted, this forecast notice provides prospective applicants with advance notice to build collaborative teams and refine innovative proposals. The initiative is part of a broader RNomics effort that also includes technology enhancement centers, molecular standards, and a coordinating center, all working toward a unified framework for RNA research. The opportunity is managed by the National Institutes of Health under the Department of Health and Human Services, and inquiries may be directed to the Common Fund RNomics Program at cfrnomics@od.nih.gov. The forecasted posting date for the formal solicitation is August 5, 2026.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

5 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
RNomics Technology Enhancement CentersThe NIH Common Fund, in partnership with multiple NIH Institutes and Centers, is forecasting the upcoming release of a Notice of Funding Opportunity for the RNomics program, specifically targeting the establishment of RNomics Technology Enhancement Centers (RTECs). These centers will focus on advancing existing RNA-related technologies with proven feasibility to enable integrated, high-resolution analysis of the full RNA landscape—spanning sequences, modifications, structures, locations, interactions, and functions—across diverse cell and tissue types. The goal is to develop robust, community-accessible tools for end-to-end RNA sequencing, precise quantitative mapping of RNA modifications, and comprehensive profiling of RNA dynamics and function, along with novel molecular and biochemical methods for manipulating and functionally testing RNA. RTECs are expected to enhance both experimental and computational platforms, driving measurable improvements in RNA measurement and analysis capabilities that benefit the broader scientific community. The initiative emphasizes scalability, reproducibility, and widespread usability, ensuring that new technologies are not only innovative but also practical for adoption across research settings. Although applications are not currently being accepted, this forecast provides potential applicants with advance notice to build collaborative partnerships and refine competitive proposals. The NIH Common Fund remains the administrative lead, with inquiries directed to cfrnomics@od.nih.gov, and the formal NOFO is anticipated to be posted in August 2026.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

5 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
RNomics Molecular StandardsThe NIH Common Fund, in collaboration with multiple NIH Institutes and Centers, is preparing to issue a Notice of Funding Opportunity for the RNomics Molecular Standards initiative under the broader RNomics program, which aims to advance the study of the complete RNA landscape in biological systems. This specific effort will focus on developing, testing, refining, and distributing molecular reference standards for RNA molecules, particularly those containing modified nucleosides and modified oligonucleotides, to ensure consistent, reproducible, and comparable measurements across diverse laboratories and technologies. The program will produce initial and expanded releases of these standards alongside guidance on their optimal selection and application, with plans to secure their long-term availability beyond the grant period to benefit the wider scientific community. These molecular standards are designed to serve as benchmarks for evaluating RNA sequencing, modification detection, and functional analysis tools, thereby enhancing data reliability and interoperability in RNA research. While applications are not currently being accepted, this forecast notice provides advance notice to investigators and institutions to foster collaboration, refine research proposals, and align their efforts with the program’s goals. The initiative is managed by the National Institutes of Health through the Department of Health and Human Services, with all inquiries directed to the Common Fund RNomics Program at cfrnomics@od.nih.gov. The anticipated posting date for the formal solicitation is August 5, 2026, and the program invites broad participation from the research community to ensure the standards meet diverse technical and scientific needs.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

5 days ago

DEADLINE

N/A
View Details
NAICS: 519290
New
Grant
RNomics Outreach and Coordination (ROC) CenterThe NIH Common Fund, in collaboration with multiple NIH Institutes and Centers, is preparing to launch the RNomics program to advance the study of the complete RNA landscape within cells and tissues, encompassing sequences, modifications, structures, locations, interactions, and functions. This initiative aims to generate transformative tools and resources that enable integrated analysis of the RNome to deepen understanding of health and disease. The program will be structured around four components: technology enhancement centers, transformative technologies, molecular standards, and a coordinating center. While no applications are currently being accepted, this forecast provides early visibility to allow potential applicants time to build strong collaborations and refine project ideas. The RNomics Outreach and Coordination (ROC) Center will serve as the central hub for the initiative, responsible for managing data infrastructure, promoting community engagement, and ensuring cross-project integration. It will develop a unified data portal, establish and support data standards, coordinate validation and benchmarking of technologies, lead large-scale data analysis efforts, and deliver training and outreach to the scientific community. The ROC Center will also be tasked with planning the long-term sustainability, accessibility, and maintenance of all RNomics data assets. Information for interested parties is available through the designated point of contact at cfrnomics@od.nih.gov, with the official solicitation expected to be released after the forecast posting date of August 5, 2026.
Web Search Portals and All Other Information Services

POSTED

5 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
Single Source Competition for Continuation of Understanding and Targeting the Pathophysiology of Youth-Onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)The DISCOVERY study is a multi-center longitudinal effort involving 19 clinical sites dedicated to identifying risk factors and biological mechanisms underlying the development of type 2 diabetes in youth during early puberty. The study is actively recruiting and following high-risk participants over time to understand the progression of the disease, with the Biostatistics Research Center serving as the central coordinating hub responsible for protocol execution, data management, quality control, statistical analysis, and seamless coordination across all participating sites. The center has built a comprehensive infrastructure to ensure data integrity and consistency throughout the prolonged follow-up period. This solicitation seeks to continue support for the existing clinical consortium to achieve its scientific goals, focusing on advancing knowledge of youth-onset type 2 diabetes pathophysiology. The funding opportunity is issued by the National Institutes of Health under the Department of Health and Human Services through a single-source competition, with no set-aside designation. The opportunity is managed by the Division of Diabetes, Endocrinology and Metabolic Diseases, and all correspondence should be directed to niddk_dem@nih.gov. The forecast was posted on August 4, 2026, and no clinical trial is permitted under this award.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

6 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Investigator-Focused Award (Parent R35)The National Institutes of Health is preparing to release a Parent R35 Investigator-Focused Award opportunity to support researchers at all career stages, including Early Stage Investigators, through a funding mechanism designed to sustain an entire program of research aligned with the mission of the awarding Institute or Center. Unlike traditional grants that fund specific projects with defined aims, the R35 provides broad, long-term support for an investigator’s scientific vision, enabling them to pursue high-risk, high-reward research without being constrained by narrow project boundaries. This award is intended to be the primary or sole source of research funding from the NIH for the recipient, offering financial stability and the freedom to adapt research directions as new opportunities emerge. The R35 award emphasizes scientific autonomy and reduced administrative burden, allowing recipients to focus more on research, mentoring, and scientific service rather than grant writing and compliance. Key advantages include the ability to follow emerging scientific leads, tackle complex and challenging questions, and foster breakthrough discoveries by encouraging broad, innovative thinking. The award is not restricted by predefined goals, giving investigators maximum flexibility to evolve their research programs over time. The solicitation is published as a forecast with a posted date of July 30, 2026, and all correspondence and inquiries should be directed to the Office of Extramural Research at parentr35@mail.nih.gov.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

11 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
INCLUDE Project: Omics Phenotypes Related to Down Syndrome (X01 Clinical Trial Not Allowed)The NIH INCLUDE Project is soliciting applications to contribute biospecimens from individuals with Down syndrome and control populations for comprehensive genomic and multi-omics analysis, aiming to uncover the molecular underpinnings of health conditions associated with Down syndrome. This initiative does not provide direct funding to applicants but encourages the submission of existing samples to generate large-scale, integrated data that will be deposited into the INCLUDE Data Hub, making it accessible to the broader scientific community to accelerate research. The focus is on omics phenotypes, with an emphasis on maximizing the scientific value of already collected biospecimens rather than collecting new ones. The opportunity is open to researchers who can align with the goal of generating high-quality, shared data resources and is not eligible for clinical trials. All data generated, including clinical and phenotypic information, will become part of a centralized repository to support collaborative discovery. The notice was posted by the National Institutes of Health under the Department of Health and Human Services, with inquiries directed to the INCLUDE Project email address, and the solicitation is available through the Grants.gov platform. Participation is contingent on the ability to deliver samples and associated metadata to designated NIH-supported resources.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

13 days ago

DEADLINE

N/A
View Details
NAICS: 541512
Grant
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)The National Institutes of Health, through the National Cancer Institute, is preparing to issue a funding opportunity aimed at advancing and sustaining high-impact informatics technologies critical to cancer research. This initiative supports tools and software that have moved beyond early-stage prototypes and demonstrate clear potential for broad application across the cancer research continuum, including cancer biology, diagnosis, treatment, early detection, risk assessment, prevention, control, and epidemiology. The program focuses on enhancing, optimizing, and disseminating existing technologies to ensure their long-term usability and adoption by the broader scientific community, with an emphasis on capabilities in data acquisition, management, analysis, visualization, and interpretation. This funding opportunity, designated as U24 and labeled as clinical trial optional, is part of the NCI’s Informatics Technology for Cancer Research Program and is open to organizations capable of scaling proven informatics resources. While no set-aside categories or NAICS codes are specified, interested applicants should note the official point of contact for inquiries is the ITCR Mailbox, reachable via email or phone. The forecasted posting date is July 28, 2026, and all details can be accessed through the Grants.gov portal. The program seeks to ensure that critical digital infrastructure remains robust, adaptable, and accessible to accelerate discoveries and improve outcomes in cancer research.
Computer Systems Design Services

POSTED

13 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Limited Competition: Institutional Mentored Research Career Development Program for the Clinical and Translational Science Awards ProgramThe National Institutes of Health is forecasting a limited competition for the Institutional Mentored Research Career Development Program under the Clinical and Translational Science Awards Program, aimed at advancing the careers of later-stage postdoctoral fellows and junior faculty dedicated to independent research in clinical and translational science. The program seeks to establish institutional frameworks that provide structured mentoring, training, and research support to ensure timely progression and long-term engagement in transformative health research that bridges laboratory discoveries with real-world patient and public health outcomes. Funding is authorized under Sections 301 and 405 of the Public Health Service Act and governed by federal regulations including 42 CFR Part 52 and 2 CFR Part 200. Only eligible organizations may apply, and submissions will undergo standard NIH peer review, with awards granted exclusively to meritorious proposals. This funding opportunity is part of the broader Congressionally mandated CTSA initiative designed to build a nationwide network of academic medical centers equipped to accelerate the translation of scientific innovation into clinical and community health improvements. The forecast was posted on July 20, 2026, and inquiries should be directed to the Division of Clinical Innovation at NCATS via the designated email address. All applications must comply with NIH guidelines and are subject to the terms of a limited competition, with no public solicitation beyond the eligible pool of institutions.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant for the Clinical and Translational Science Awards ProgramThe National Institutes of Health, under the Department of Health and Human Services, is forecasting a limited competition for the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant aimed at advancing clinical and translational science. This initiative supports accredited academic medical centers in developing comprehensive training programs for predoctoral and postdoctoral researchers, equipping them with the skills and infrastructure necessary to translate scientific discoveries into effective patient care and public health interventions. The program is aligned with the broader Congressionally mandated Clinical and Translational Science Award (CTSA) initiative, which fosters a national network of institutions dedicated to accelerating the movement of research from laboratory to clinic and community. Funding is authorized under Sections 301 and 405 of the Public Health Service Act and governed by federal regulations including 42 CFR Part 52 and 2 CFR Part 200. Only eligible organizations invited through the limited competition may submit applications, which will undergo standard NIH peer review to determine merit and funding eligibility. The opportunity is managed by the Division of Clinical Innovation at the National Center for Advancing Translational Sciences, with inquiries directed to a designated point of contact. The forecast was posted on July 20, 2026, and interested parties are encouraged to review eligibility criteria and application guidelines through the official Grants.gov portal.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 923120
Grant
Limited Competition: Research Education Program for the Clinical and Translational Science Awards ProgramThe Congressionally mandated Clinical and Translational Science Award Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by establishing a national network of academic medical centers equipped with the infrastructure, expertise, training, and collaborative frameworks necessary to bridge laboratory research with clinical and community practice. This forecasted limited competition seeks to support research education activities that complement and strengthen the training of a skilled workforce capable of addressing the nation’s demands in biomedical, behavioral, and clinical research, aligning with the broader goals of the CTSA Program. Awards will be issued under the authority of Sections 301 and 405 of the Public Health Service Act as amended and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Only eligible organizations may apply, and submissions will undergo the National Institutes of Health’s standard peer-review process, with funding reserved for the most meritorious proposals. The opportunity is open to a restricted pool of applicants as defined in the eligibility criteria, with applications to be submitted through the official grants portal, and inquiries should be directed to the Division of Clinical Innovation at NCATS.
Administration of Public Health Programs

POSTED

21 days ago

DEADLINE

N/A
View Details